News

KUORI Enters B2C with Filament Built for Next-Gen Makers

Zurich, Switzerland – 05. December 2025 A game changer for the next generation of circular makers: Swiss cleantech startup KUORI is shaking up the world of material and product design with the launch of a 3D printing filament based on its flagship material BIOWA, a bio-based, biodegradable and recyclable thermoplastic...

read more

Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting

Schlieren / Zurich, Switzerland, 7 November, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that it has presented long term follow-up data from its Phase II SAFE KIDNEY trial of therapeutic antibody potravitug for the...

read more

DINAMIQS obtains ExcellGene’s HEKExpress® and HEK2Express® cell line technologies for viral vector GMP manufacturing

DINAMIQS, a Siegfried company, today announced a licensing agreement with ExcellGene to access its HEKExpress® and HEK2Express® suspension cell line technologies. These will be used in GMP manufacturing of recombinant Adeno-associated virus (rAAV) and Lentivirus (rLV) vectors for both in-vivo and ex-vivo gene therapies. Eduard Ayuso, Chief Technical Officer at DINAMIQS:...

read more

Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the formation of a Scientific Advisory Board (SAB) for its radiopharmaceuticals,...

read more